Today, BARDA announced plans to provide $176 million in funding to Moderna for the development of pandemic influenza mRNA-based vaccines. This award will help speed the development of additional pandemic influenza vaccine response capacity.
During a pandemic, the rapid development and deployment of vaccines helps slow the spread of disease, saving lives. The work done under this agreement would also allow for development and manufacturing to pivot more quickly, if needed, to address emerging infectious diseases and other health security threats. To find out how this new award helps bolster pandemic preparedness, read our latest press release. https://lnkd.in/e8qkk5nq